Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review

Date: April 11, 2018
Pages: 57
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G8C59F02242EN
Leaflet:

Download PDF Leaflet

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review
Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company also has a wide range of pipeline products in various therapeutic areas in different stages of development. Gilead sells its products through marketing subsidiaries and distributors and corporate partners in Europe, the Americas, Asia-Pacific, the Middle East and Africa. The major products of the company include Harvoni, Sovaldi, Truvada, Atripla, Stribild, Epclusa, Genvoya, Complera/Eviplera, Viread and others. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc Key Recent Developments

Mar 12,2018: Gilead Sciences Announces Senior Management Changes
Mar 05,2018: Epilepsy Foundation Awards $200,000 at ‘Shark Tank’ Competition for Innovative Products that Aim to Improve Epilepsy Treatment and Care
Feb 28,2018: Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan
Feb 23,2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL
Feb 22,2018: Gilead Sciences Announces Senior Management Change

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

Gilead Sciences Inc - Key Facts
Gilead Sciences Inc - Key Employees
Gilead Sciences Inc - Key Employee Biographies
Gilead Sciences Inc - Major Products and Services
Gilead Sciences Inc - History
Gilead Sciences Inc - Company Statement
Gilead Sciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Gilead Sciences Inc - Business Description
Product Category: Antiviral Products
Overview
Performance
Product Category: Other Products
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: United States
Performance
R&D Overview
Gilead Sciences Inc - SWOT Analysis
SWOT Analysis - Overview
Gilead Sciences Inc - Strengths
Gilead Sciences Inc - Weaknesses
Gilead Sciences Inc - Opportunities
Gilead Sciences Inc - Threats
Gilead Sciences Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Gilead Sciences Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 05, 2018: Epilepsy Foundation Awards $200,000 at ‘Shark Tank’ Competition for Innovative Products that Aim to Improve Epilepsy Treatment and Care
Feb 28, 2018: Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan
Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL
Feb 22, 2018: Gilead Sciences Announces Senior Management Change
Feb 19, 2018: Gilead wins reversal in $2.5 billion dispute with Merck
Feb 06, 2018: Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results
Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs
Dec 14, 2017: Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
Dec 04, 2017: Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States
Nov 03, 2017: Abraham Brass receives grant from Gilead for HIV research

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Gilead Sciences Inc, Key Facts
Gilead Sciences Inc, Key Employees
Gilead Sciences Inc, Key Employee Biographies
Gilead Sciences Inc, Major Products and Services
Gilead Sciences Inc, History
Gilead Sciences Inc, Other Locations
Gilead Sciences Inc, Subsidiaries
Gilead Sciences Inc, Joint Venture
Gilead Sciences Inc, Key Competitors
Gilead Sciences Inc, Ratios based on current share price
Gilead Sciences Inc, Annual Ratios
Gilead Sciences Inc, Annual Ratios (Cont.1)
Gilead Sciences Inc, Annual Ratios (Cont.2)
Gilead Sciences Inc, Interim Ratios
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Gilead Sciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Gilead Sciences Inc, Performance Chart (2013 - 2017)
Gilead Sciences Inc, Ratio Charts
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Wave 80 Biosciences Inc
United Therapeutics Corp
Quanta BioDesign Ltd
Ocera Therapeutics Inc
Novartis AG
Merck & Co Inc
Janssen Therapeutics
Islet Sciences Inc
Intercept Pharmaceuticals Inc
hVIVO Plc
GlaxoSmithKline Plc
Enzon Pharmaceuticals Inc
Celgene Corp
Boehringer Ingelheim GmbH
BioVentures Inc
Actelion Pharmaceuticals US Inc
Abbott Laboratories
Skip to top


Ask Your Question

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: